Nykode Therapeutics AS (VACBF)
OTCMKTS
· Delayed Price · Currency is USD
0.1950
0.00 (0.00%)
At close: Jul 11, 2025
Nykode Therapeutics AS Employees
As of December 31, 2024, Nykode Therapeutics AS had 136 total employees, including 135 full-time and 1 part-time employees. The number of employees decreased by 37 or -21.39% compared to the previous year.
Employees
136
Change (1Y)
-37
Growth (1Y)
-21.39%
Revenue / Employee
$110,387
Profits / Employee
-$337,613
Market Cap
55.96M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
CytoDyn | 9 |
American Oncology Network | 1,914 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 116 |
Nykode Therapeutics AS News
- 8 months ago - Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe - GlobeNewsWire
- 11 months ago - Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer - GlobeNewsWire
- 1 year ago - Nykode Therapeutics - Quarterly report Q1 2024 - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer - GlobeNewsWire